Description of Tafnat
Trade Name: Tafnat Active Ingredient: Tenofovir Alafenamide (TAF) 25mg
Manufacture: Natco Packing: Pack of 30 tablets
category: Anti-retroviral agent
Tafnat tablet prohibits the multiplication of HIV (human retro virus) and chronic hepatitis B (HBV) virus in human cells. Thus prevents the hepatitis B and HIV virus from developing new viruses.
o Tafnat, an anti retroviral drug contains Tenofovir Alafenamide fumarate (TAF) as a active key ingredient.
o TAF is a nucleotide reverse transcriptase inhibitor (NRTI) which involves in the treatment of HIV infection and chronic hepatitis B infection.
o TAF is closely associated with reverse-transcriptase inhibitor Tenofovir disoproxil fumarate (TDF)
o Even if the TAF has a good drug safety profile and efficacy, it has some demerits like nephrotoxicity and which reduced bone mineral density.
Pharmacology of Tafnat
Tafnat contains an ingredient Tenofovir Alafenamide Fumarate; which is nucleotide reverse transcriptase inhibitor.
TAF is an ester prodrug of anti-retroviral, Tenofovir.
TAF is converted into tenofovir in vivo by using acyclic nucleoside phosphonate
Drug tenofovir decrease the normal DNA building blocks by lacking of OH molecules which is essential for phosphodiester bond linkage.
The phosphodiester bond linkage is responsible for DNA elongation
This leads to chain termination and prevents proviral DNA transcription.
The absorption of tablet Tafnat is normally high. Tmax is monitored at 1 hour after oral administration of tablet Tafnat
Tenofovir Alafenamide fumarate is highly bound to plasma protein; nearly 80% of drug is bounds to protein.
TAF is hydrolyzed into Tenofovir which is occurs within the cells, it is a major metabolite.
Tenofovir is phosphorylated into active metabolite called tenofovir diphosphate.
Metabolism occurs by cathepsin A (Liposomal Protective Protein) in peripheral blood mononuclear cells and macrophages; and by Carboxyl esterase 1 (CES1) in hepatocytes.
The half life period of tablet Tafnat is 0.51 hour.
Indication of Tafnat
Tafero tablet Indication:
Tafnat commonly used for the treatment of HIV infection and chronic hepatitis B infection (HBV).
Tafnat involved in the treatment of chronic hepatitis (HCV) genotype I, II, III, IV, V &VI.
Dose & Dosage's of Tafnat
Tafnat tablet is administered as single dose it is recommended for adolescent.
The recommended dose of Tafnat tablet is 25mg
Tafnat should be taken with food.
Take one time each day
If patient fail to take a dose of Tablet Tafnat means, it should be taken within the time.
Patient should skip the dose and follow the regular drug dose schedule
Do not take two doses at the same time
Side Effects of Tafnat
Tafnat tablets Side effects:
Feeling sick and more.
Serious side effects like;
Mental/mood chances: depression, anxiety, confusion
Signs of kidney problems
Liver and blood problems
Allergic reactions: rash, itching/swelling, dizziness, trouble breathing.
An adverse effect occurs during the therapy;
Depression, asthenia, nausea, abdominal pain, insomnia, Pruritus, pyrexia
Pancreatitis, abdominal pain, elevated amylase, flatulence, dyspepsia, abdominal distension, elevated serum lipase
Lactic acidosis, severe hepatomegaly with steatosis, hypokalemia, and hypophosphatemia, elevated fasting cholesterol, elevated triglycerides
With an anti retroviral treatment: accumulation of body fat occurs, lead to obesity
Pruritus, lipodystrophy, angioedema, Eosinophilia,
Insomnia, depression, anxiety, abnormal dreams
Headache, dizziness, peripheral neuropathy, somnolence, paresthesia
Pyrexia, asthenia, fatigue, weight loss, chest pain, increased weight, procedural pain
Increased creatine kinase
Arthralgia, Myalgia, back pain, rhabdomyolysis, muscle weakness, myopathy, bone abnormalities, fractures, osteonecrosis, osteomalacia
Elevated transaminase elevated ALT, AST, hepatic steatosis, elevated liver enzymes
Increased creatinine, proximal renal tubulopathy (Fanconi syndrome), acute renal failure, acute tubular necrosis, nephrogenic diabetes insipidus, renal insufficiency, interstitial nephritis
Sinusitis, upper respiratory tract infection, Nasopharyngitis, pneumonia, pharyngolaryngeal pain, nasal congestion, dyspnea
Hematuria, glycosuria, decreased urine volume, Proteinuria, polyuria
Increased serum parathyroid hormone levels
GraveÃ¢â‚¬â„¢s disease, polymyositis, Guillain-Barre syndrome
Contraindication of Tafnat
The following conditions are contraindicated; while using Tafnat tablet
Softening of bones, low amount of phosphate in blood, elevation in blood acidity due to high levels of lactic acid, fanconiÃ¢â‚¬â„¢s syndrome, enlarged fatty liver, acute kidney failure, depletion of bone density, broken bone due to disease
Drug Interaction of Tafnat
Tafero tablet Indication: Tafnat commonly used for the treatment of HIV infection and chronic hepatitis B infection (HBV). Tafnat involved in the treatment of chronic hepatitis (HCV) genotype I, II, III, IV, V &VI.
Precaution of Tafnat
If patient having lactic acidosis and severe hepatomegaly with steatosis, care should be taken while that patient treated with Tafnat (TAF)
Lactic acidosis/severe hepatomegaly with steatosis
Severe acute exacerbation of Hepatitis B after the treatment
Risk of development of HIV-1 resistance in patientÃ¢â‚¬â„¢s co infected with HBV and HIV-1
Obesity is also one of the risk factor
Tafnat is safe to use in liver problem containing patient but it is contraindicated to kidney failure.
Usage & Safety profile of Tafnat Pregnancy & Lactation
In both conditions, tablet Tafnat is safe to use; but prior information given to physician in case of pregnancy condition. There is a chance of placental transformation during labor Pediatric and geriatric usage not recommended.
Storage of Tafnat
Tafnat is stored under temperature at 30oC (86oF).